As a result of the rapid expansion of cell and gene therapy research and development in the Asia-Pacific region, regulatory organizations have created a framework for supporting accelerated marketing authorizations for these treatments in order to address unmet medical needs.

Many biotech and pharmaceutical companies are leveraging on these new regulatory pathways for advanced therapies to bring these innovative medicines into Asia-Pacific. But who are the market players and which therapeutics are they focused on?



Explore over 1000 Cell & Gene therapies from more than 300 companies including Biopharma, Big Pharma, CMOs and Research Academic Institutes across multiple therapeutic areas of focus in Asia-Pacific region. This unique data gives you access to broad coverage of both Cell & Gene Therapy Pipeline and Manufacturing, in a single platform. It tracks Cell & Gene Therapy market from over 11 APAC countries including South-Korea, Japan, China, Taiwan, India, Australia, Singapore, Malaysia, Indonesia, Thailand and Hong-Kong among others.

The data is covered across several parameters to provide real-time insights into cell & gene therapy industry such as the list of APAC based CGT companies, cell therapy products, gene therapies, viral & non-viral therapies, allogenic vs autologous therapies, cell & gene therapy pipelines across all stages of development, route of administration for drug candidates and targets, indications, technology platform used in the development, manufacturing of cell and gene therapy products, clinical and commercial production, in-house manufacturing capabilities of cell and gene therapy companies, clinical trial projects, cell and gene therapy manufacturing facilities, production capacity, upstream and downstream processing capabilities, cell therapy processing equipment and technologies and other detailed information on cell and gene therapy developers and manufacturers.

Examples of CGT companies included in this data are top pharmaceutical companies such as Novartis AG, Gilead Sciences, JCR Pharmaceuticals and other biopharmaceutical companies including Kolon Life Sciences, Medipost, Curocell, Anges MG, Anterogen, X-Cell therapeutics and many others. Some of the research and academic institutes covered in this tracker are Biostar Stem Cell Research Institute, Chiba University, National Cancer Center in Japan and Peking University in addition to CDMO/CMOs including XCell Therapeutics, Lonza, Bora Pharmaceuticals, Cell Therapeutics Ltd and other top cell & gene therapy manufacturers in the APAC region.

The data is underpinned by user-friendly visuals to allow users to filter through data by cell and gene therapy company, country, product type, cell therapy types, viral vectors types, scale of stage of development, therapy focus area, company founded year, type of company, manufacturing facility location, facility size range, expression system, batch/continuous process, bioreactor type facility operational year, batch size of products and facility counts in a particular APAC country.

Pick the right plan!

From evolving customer expectations and emerging technologies to more nimble companies entering industries, businesses today are more at risk for disruption than ever before.
6 Months
  • Access for 6 months
  • Single user
  • Monthly Updates
1 Year
  • Access for 1 year
  • Single User
  • Monthly Updates

Key Parameters

  • Cell & Gene therapy companies
  • Company description
  • Company website
  • Company founded year
  • Company headquarters or business unit location
  • Company type (Biopharma, Big-Pharma, CMO/CDMOs, Academic/Research Institutes)
  • Company operational status (Active/Inactive)
  • Number of products candidates in APAC
  • Candidate in pipeline
  • Products in stages of development (From discovery to commercialization)
  • Products by product type (Cell therapy, gene therapy, gene-modified cell therapy, other regenerative therapy)
  • Products by therapy type (Including CAR-T, TCR-T, NK-CELL, MSC Cell, AAV, Stem cell, CAR-CIK, CAR-GDT, Dendritic Cell, Targeted Therapy, Immune Cell, T-Cell, TILS, U-CART)
  • Disease or indication
  • Therapy focus area
  • Target for each product candidate
  • Route of administration
  • Autologous or allogenic therapies
  • Technology platform (Including Next generation technology, Conventional, Donor-derived CAR platform, Gene editing techniques, Universal and proprietary technology platforms)
  • Viral or non-viral therapy
  • Vector type (Including AAV types, Adenovirus, Lentivirus, Oncolytic virus, Retro virus)
  • Sponsors or partners for CGT development
  • Manufacturing capability of CGT company

Regions Coverage

South Korea, China, Japan, Taiwan, Australia, Singapore, India, Malaysia, Indonesia, Thailand, Hong Kong

Key Manufacturing Parameters

  • CGT focused manufacturing company
  • CGT manufacturing facility location
  • Type of company (Biopharma, Big-Pharma, CMO/CDMOs, Academic/Research Institutes)
  • Number of facilities
  • Facility name
  • Facility size
  • Facility established year
  • Facility production capacity
  • Facility investment (In Million USD)
  • Features of facilities
  • Production type (Specific cell therapy or gene therapy products manufactured)
  • Production stage (Clinical/Commercial)
  • Technology platform
  • Regulatory approval & compliance
  • Expansion plans
  • Expression systems
  • Batch/continuous manufacturing
  • Bioreactor type
  • Batch size
  • Sponsors or Partners of CGT manufacturers
  • Other updates

Product Types Covered

Gene Therapy

Cell Therapy

How This Data Will Benefit?

It presents over 730 biopharma and CMO/CDMO facilities data from more than 11 Asia-pacific countries including South-Korea, Japan, China, Australia, India, Singapore, Indonesia, Taiwan. We ensure delivery of highly-qualified research as we tap into our database of 62000+ life science professionals curated over a decade.

The data provides an in-depth overview of the upcoming competition in the Asian Bioprocessing market. Through this tracker IMAPAC aims to assist organizations to keep track of their competitors, identify any opportunities for collaboration or investments for development or manufacturing of large molecules in the Asia-Pacific region, aiding in key strategic decisions for biopharma business industry.

Data Methodology

The data is researched and validated using primary and secondary research. The data is collected through multiple scientific and non-scientific sources including live discussions with experts through IMAPAC’s events and research reports, survey polls, company websites, press releases, publicly available information, regulatory database and many more.

We have a database of key decision makers from the biopharma and big pharma companies across the region. We host industry surveys with leaders of Biopharma and CMOs, and host primary interviews with Heads of R&D, Manufacturing, Process Development Heads and multiple stakeholders in the companies to gather data as well as validate that data using our primary research analysts.

Throughout the year, we keep in touch with the KOLs through telephonic Conversation, with Q&A sessions with high profile biopharma professionals, for example CSO/CTO profiles. Apart from telephonic conversations, we send a list of questions which these experts fill in detail and send back to us.

We have dedicated analysts who gather data. The data included is validated through primary research (interviews, phone calls) with stakeholders which is then validated by IMAPAC’s research analysts to ensure the accuracy of the data.

Key Questions Answered

  • How many Cell & Gene Therapy (CGT) companies are operating in Asia?
  • Where are these CGT companies set up across Asia?
  • Which types of companies are focusing on CGT products development and manufacturing?
  • How many CGT products are in pipeline across APAC region?
  • What is the status of CGT products in different stages?
  • Which are the different indications and disease therapy focus areas for CGT products?
  • Which donor type therapy (allogenic or autologous) is preferred in cell therapy treatment?
  • What are some technology platforms employed by the CGT companies?
  • Does CGT companies have in-house manufacturing capabilities or outsourcing to expert CMOs?
  • Where is CGT focused manufacturing plants located in Asia?
  • What is an average size of manufacturing facility for CGT production?
  • What type of specific cells or gene therapy products are manufactured in Biopharma and CMO facilities?
  • Which regulatory compliance guidelines and certifications are followed by CGT manufacturers?
  • What is the production capacity and batch size for cell and gene therapies production?
  • How much investment is made in each facility?
  • Which type of process technology or bioanalytic equipment used in the manufacturing of CGT products?
  • What are the future plans of CGT companies and manufacturers in terms of investments, facility extension, partnership, addition of new suites, innovation labs, updates on bio-reactor use and production and shift from clinical to commercial stage of production?
  • Who are the partners or investors involved in the CGT development and manufacturing?

Data Sample